Publication:
Recurrence rate of hirsutism after 3 different antiandrogen therapies

dc.contributor.authorsYucelten, D; Erenus, M; Gurbuz, O; Durmusoglu, F
dc.date.accessioned2022-03-12T16:58:04Z
dc.date.accessioned2026-01-11T15:09:40Z
dc.date.available2022-03-12T16:58:04Z
dc.date.issued1999
dc.description.abstractBackground: Although antiandrogens are frequently and successfully used to treat hirsutism, little attention has been paid to optimal duration of treatment and recurrence rate after cessation of therapy. Objective: Our purpose was to determine the recurrence rate of hirsutism after 3 different antiandrogen therapies. Methods: Eighty-one hirsute women referred to a tertiary hirsutism clinic were assigned to one of three regimens: spironolactone 100 mg/day with an oral contraceptive, cyproterone acetate 50 mg/day on days 1 to 10 with an oral contraceptive, or flutamide 250 mg twice a day. Hirsutism scores according to the Ferriman-Gallwey scoring system and endocrine parameters were evaluated before, during, and 1 year after withdrawal of treatment regimens. Results: Hirsutism scores decreased significantly and similarly in spironolactone, flutamide, and cyproterone acetate treatment groups. However, 1 year after withdrawal of treatment in all antiandrogen therapy groups, hirsutism returned. Conclusion: Antiandrogens are effective in the treatment of hirsutism. However cessation of antiandrogen therapy is followed by recurrence.
dc.identifier.doi10.1016/S0190-9622(99)70408-1
dc.identifier.issn0190-9622
dc.identifier.pubmed10411413
dc.identifier.urihttps://hdl.handle.net/11424/227007
dc.identifier.wosWOS:000081259600011
dc.language.isoeng
dc.publisherMOSBY-YEAR BOOK INC
dc.relation.ispartofJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCYPROTERONE-ACETATE-ESTROGEN
dc.subjectRANDOMIZED CONTROLLED TRIAL
dc.subjectFLUTAMIDE
dc.subjectSPIRONOLACTONE
dc.subjectEFFICACY
dc.subjectMETABOLISM
dc.subjectREMISSION
dc.titleRecurrence rate of hirsutism after 3 different antiandrogen therapies
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage68
oaire.citation.issue1
oaire.citation.startPage64
oaire.citation.titleJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
oaire.citation.volume41

Files